The marine-derived oligosccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in Vitro and in Vivo

PLoS ONE

Volumn 3, Issue 11, 2008, Pages

  Ma, Jingui ^a   Xin, Xianliang ^a   Meng, Linghua ^a   Tong, Linjiang ^a   Lin, Liping ^a   Geng, Meiyu ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MARINE DERIVED OLIGOSACCHARIDE SULFATE; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; OLIGOSACCHARIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SULFATE;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; VASCULAR RING; VASCULAR TUMOR; WESTERN BLOTTING; ANIMAL; AORTA; CHEMISTRY; CHICKEN; CHORIOALLANTOIS; DRUG ANTAGONISM; IN VITRO STUDY; KINETICS; METABOLISM; MICROCIRCULATION; NEOPLASM; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

RATTUS;

ANIMALS; AORTA; CELL LINE, TUMOR; CHICKENS; CHORIOALLANTOIC MEMBRANE; ENDOTHELIUM, VASCULAR; HUMANS; KINETICS; MICROCIRCULATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOSACCHARIDES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; SULFATES;

EID: 56849098340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003774     Document Type: Article

References (39)

1. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, et al. (2001) Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 21: 499-512.
2. Madhusudan S, Ganesan TS (2004) Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 37: 618-635.
3. Baselga J (2006) Targeting tyrosine kinases in cancer: the second wave. Science 312: 1175-1178.
4. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411: 355-365.
5. Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1: 117-123.
6. Druker BJ (2004) Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91: 1-30.
7. Herbst RS, Fukuoka M, Baselga J (2004) Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 4: 956-965.
8. Baselga J, Albanell J (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 Suppl 1: S35-41.
9. Klein S, Levitzki A (2007) Targeted cancer therapy: promise and reality. Adv Cancer Res 97: 295-319.
10. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24.
11. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, et al. (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13: 1367-1373.
12. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, et al. (2007) Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12: 107-113.
13. Kane RC, Farrell AT, Saber H, Tang S, Williams G, et al. (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271-7278.
14. Sawyers CL (2001) Research on resistance to cancer drug Gleevec. Science 294: 1834.
15. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
16. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
17. Lazaro I, Gonzalez M, Roy G, Villar LM, Gonzalez-Porque P (1991) Description of an enzyme-linked immunosorbent assay for the detection of protein tyrosine kinase. Anal Biochem 192: 257-261.
18. Lin LG, Xie H, Li HL, Tong LJ, Tang CP, et al. (2008) Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening. J Med Chem 51: 4419-4429.
19. Zhang XH, Guo XN, Zhong L, Luo XM, Jiang HL, et al. (2007) Establishment of the active catalytic domain of human PDGFRbeta tyrosine kinase-based ELISA assay for inhibitor screening. Biochim Biophys Acta 1770: 1490-1497.
20. Miao B, Li J, Fu X, Gan L, Xin X, et al. (2005) Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits T cell apoptosis by combating oxidative damage of mitochondria. Mol Pharmacol 68: 1716-1727.
21. Arteaga C (2003) Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 30: 3-14.
22. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974.
23. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
24. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, et al. (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9: 1546-1556.
25. Staton CA, Stribbling SM, Tazzyman S, Hughes R, Brown NJ, et al. (2004) Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol 85: 233-248.
26. Baselga J, Arribas J (2004) Treating cancer's kinase 'addiction'. Nat Med 10: 786-787.
27. Maione P, Gridelli C, Troiani T, Ciardiello F (2006) Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 11: 274-284.
28. Sosman JA, Puzanov I, Atkins MB (2007) Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 13: 764s-769s.
29. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, et al. (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764-5769.
30. Blencke S, Ullrich A, Daub H (2003) Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 278: 15435-15440.
31. Cole CL, Jayson GC (2008) Oligosaccharides as anti-angiogenic agents. Expert Opin Biol Ther 8: 351-362.
32. Zhong L, Guo XN, Zhang XH, Wu ZX, Luo XM, et al. (2005) Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening. Biochim Biophys Acta 1722: 254-261.
33. Zhang YX, Chen Y, Guo XN, Zhang XW, Zhao WM, et al. (2005) 11,11′-dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity. Anticancer Drugs 16: 515-524.
34. Guo XN, Zhong L, Zhang XH, Zhao WM, Zhang XW, et al. (2004) Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochim Biophys Acta 1673: 186-193.
35. Li F, Geng M, Li Y, Li J, Miao B, et al. (2002) Studies on Fluorescent Labeling of Marine Sulfated Polysaccharide 911. Chemical Research In Chinese Universities 9: 1704-1708.
36. Matthew Clark RDCI, Nicole Van Opdenbosch (1989) Validation of the general-purpose tripos 5.2 force-field. J Comput Chem 10: 982-1012.
37. Johann Gasteiger MM (1980) Iterative partial equalization of orbital electronegativity a rapid access to atomic charges. Tetrahedron 36: 3219-3228.
38. Kuntz ID (1992) Structure-based strategies for drug design and discovery. Science 257: 1078-1082.
39. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8: 127-134.